Travere Therapeutics, Inc.TVTXEarnings & Financial Report
Nasdaq
TVTX Q3 2025 Key Financial Metrics
Revenue
$164.9M
Gross Profit
$163.3M
Operating Profit
$24.9M
Net Profit
$25.7M
Gross Margin
99.0%
Operating Margin
15.1%
Net Margin
15.6%
YoY Growth
162.1%
EPS
$0.28
Financial Flow
Travere Therapeutics, Inc. Q3 2025 Financial Summary
Travere Therapeutics, Inc. reported revenue of $164.9M for Q3 2025, with a net profit of $25.7M (15.6% margin). Cost of goods sold was $1.6M, operating expenses totaled $138.3M.
Key Financial Metrics
| Total Revenue | $164.9M |
|---|---|
| Net Profit | $25.7M |
| Gross Margin | 99.0% |
| Operating Margin | 15.1% |
| Report Period | Q3 2025 |
Travere Therapeutics, Inc. Annual Revenue by Year
Travere Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $233.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $233.2M |
| 2023 | $145.2M |
| 2022 | $212.0M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-8.5M | $41.4M | $54.1M | $62.9M | $74.8M | $81.7M | $114.4M | $164.9M |
| YoY Growth | -115.3% | -27.4% | -9.3% | 69.6% | 975.0% | 97.5% | 111.5% | 162.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $788.9M | $663.5M | $551.1M | $504.4M | $594.1M | $548.8M | $555.3M | $538.6M |
| Liabilities | $588.1M | $589.5M | $536.0M | $534.9M | $535.0M | $516.0M | $522.6M | $465.0M |
| Equity | $200.8M | $74.1M | $15.1M | $-30.5M | $59.1M | $32.8M | $32.7M | $73.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-70.5M | $-119.0M | $-40.2M | $-42.5M | $-35.7M | $-42.2M | $5.0M | $14.3M |